-- Asymchem Laboratories（HKG：6821、SHG：002821）は、第1四半期の株主帰属純利益が3億430万元となり、前年同期の3億2660万元から6.8%減少したことを明らかにした。
同社の香港上場株は、火曜日の正午の取引で8%近く上昇した。
1株当たり利益は0.84元で、前年同期の0.89元から減少した。
売上高は前年同期の15億4000万元から17%増加し、18億元となった。
Related Articles
International
U.S. Energy Production Climbs 3% YoY in January, EIA Reports
U.S. primary energy production rose 3% year over year in January to 9.1 quadrillion British thermal units, the U.S. Energy Information Administration said in its Monthly Energy Review released Monday.Total fossil fuels production in January was made up of 46% dry natural gas, 31% crude oil, 12% crude oil and 11% natural gas plant liquids, the EIA reported.Total renewable energy production was composed of 56% biomass, 20% wind, 12% hydroelectric power, 11% solar and 1% geothermal energy, according to the agency.U.S. natural gas plant liquids production was 7% higher in January than in the year-ago month. Dry natural gas production and renewable energy production each climbed 4%. Nuclear electric power production and coal production each increased 2%. Crude oil production rose 1%.
$CLX1$LCOX1$NGV1$UNG$UNL$USO
Asia
CanSino Biologics Widens Loss in Q1
CanSino Biologics (HKG:6185, SHA:688185) widened its attributable loss in the first quarter of 2026 to 40.4 million yuan from 11.5 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.Loss per share was 0.16 yuan, compared with 0.05 yuan in the corresponding period of the previous fiscal year.Operating revenue jumped 39% to 190.3 million yuan from 137.2 million yuan in the year-ago period, amid the company's expanding commercial product portfolio, increasing overseas presence, and robust sales of hte MCV4 vaccine.The vaccine manufacturer attributed the wider loss to a higher operating cost; a rise in selling, administrative, and R&D expenses; and a lower other income related to government grants and international funding support.
$HKG:6185$SHA:688185
Japan